BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
BioXcel Therapeutics Inc BTAI
News
-
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
BioXcel Therapeutics Announces Termination of Proposed Public Offering
Thinking about buying stock in BioXcel Therapeutics, Hitek Global, Abeona Therapeutics, Mullen Automotive, or Intuitive Machines?
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BioXcel Therapeutics Announces Proposed Public Offering
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
Thinking about buying stock in Cano Health, Vaxart, Macy's, Albemarle Corp, or BioXcel Therapeutics?
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
BioXcel Therapeutics Shares Sink After Weak 3Q
BioXcel Therapeutics shares pop after audit of Alzheimer's trial data
